Pembrolizumab plus EVX-01, a personalized peptide-based neoantigen cancer vaccine, demonstrated the “ability to induce potent and sustained T-cell responses” among patients with previously untreated, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback